1. Scrip
  2. >>Therapy Areas
  3. >>Musculoskeletal

Selecta chooses Takashi Kei Kishimoto for CSO

 
• By Gemma Sharman

Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Dr Takashi Kei Kishimoto chief scientific officer reporting to Dr Werner Cautreels, Selecta's CEO. Dr Kishimoto most recently served as vice-president of research at Momenta Pharmaceuticals, where he led a team advancing novel and complex generic products for inflammation, oncology and cardiovascular disease.

Selecta Biosciences, a biopharmaceutical company developing novel targeted vaccines and immunotherapies, has appointed Dr Takashi Kei Kishimoto chief scientific officer reporting to Dr Werner Cautreels, Selecta's CEO. Dr Kishimoto most recently served as vice-president of research at Momenta Pharmaceuticals, where he led a team advancing novel and complex generic products for inflammation, oncology and cardiovascular disease.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Musculoskeletal

More from Therapeutic Category

Who Dares Wins? Roche Moves Parkinson’s Candidate Into Phase III Despite Near Miss

 
• By Andrew McConaghie

Open-label extension data have persuaded Roche to move prasinezumab into Phase III, where it believes a few tweaks to the study design could turn a near miss into success.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: breaking down big pharma’s executive pay; US vaccine panel upheaval; Merck’s RSV approval; MFN and Japan; and the future of Pfizer and Arvinas’s partnership.

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.